Palbociclib and Breast Cancer Therapy

Palbociclib has several direct competitors currently on the market or in clinical trials. In September 2017, abemaciclib , another selective CDK4/6 inhibitor owned and manufactured by Eli Lilly , was approved for HR-positive, HER2-negative advanced metastatic breast cancer both in combination with fulvestrant and as a monotherapy . In March 2017, the FDA also approved ribociclib , owned by Novartis , as a combination therapy with aromatase inhibitors for indications similar to those of palbociclib and ribociclib.

Leave a Reply

Your email address will not be published. Required fields are marked *



Local News


About Us

Follow Us

Skip to toolbar